Grades 1 and 2 hypothyroidism in a state mental hospital: risk factors and clinical findings.
Thirty-six chronically psychotic patients (nine men and 27 women, mean age 56.7 +/- S.D. 13.4 years) were found to have elevated thyroid stimulating hormone (TSH) levels during review of thyroid function screening tests of 1150 patients over a 15 month period in a 700 bed state mental hospital. This study population of 36 patients was more likely to be female and older than the general hospital population. The spectrum and frequency of psychiatric diagnoses included dementia (3); schizoaffective disorder (12); bipolar disorder (6); schizophrenic disorder (4); organic affective disorder (7); major depression (3); and mental retardation (1). Only nine of these 36 patients failed to receive the goitrogens lithium (LI), carbamazepine (CBZ) and/or phenytoin (PTN) and five of those nine patients had a history of thyroid disease. Sex did not predict age, thyroxine (T4) level, triiodothyronine (T3) uptake, or TSH. The distribution of psychiatric diagnoses were the same for both sexes. Expectedly, there was an inverse relationship between TSH and T4 and T3 uptake. Using T4 to separate grades 1 and 2 hypothyroidism revealed that six (17%) patients had grade 1 disease. Men were more likely to have a seizure disorder and receive LI, CBZ, and PTN. Women were more likely to have a history of thyroid disease. The goitrogenic effects of LI + CBZ seemed additive compared with patients receiving LI alone. While T4, T3 uptake, and LI levels were the same for the two groups, patients receiving LI + CBZ had higher TSH values (p = 0.028) than did patients receiving LI alone.(ABSTRACT TRUNCATED AT 250 WORDS)
D000328:Adult; D000367:Age Factors; D000368:Aged; D002220:Carbamazepine / Q000009:adverse effects*; D004359:Drug Therapy, Combination; D005260:Female; D006778:Hospitals, Psychiatric; D006783:Hospitals, State; D006801:Humans; D007037:Hypothyroidism / Q000139:chemically induced*; D008094:Lithium / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D010672:Phenytoin / Q000009:adverse effects*; D011618:Psychotic Disorders / Q000150:complications / Q000188:drug therapy; D012306:Risk; D013972:Thyrotropin / Q000097:blood; D013973:Thyrotropin-Releasing Hormone; D013974:Thyroxine / Q000097:blood; D014284:Triiodothyronine / Q000097:blood; D014768:Virginia
D014284:Triiodothyronine; D002220:Carbamazepine; D013973:Thyrotropin-Releasing Hormone; D010672:Phenytoin; D013972:Thyrotropin; D008094:Lithium; D013974:Thyroxine